Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 12;11(1):15.
doi: 10.1186/s13550-021-00754-1.

Quantitation of cancer treatment response by 2-[18F]FDG PET/CT: multi-center assessment of measurement variability using AUTO-PERCIST™

Affiliations

Quantitation of cancer treatment response by 2-[18F]FDG PET/CT: multi-center assessment of measurement variability using AUTO-PERCIST™

Joo Hyun O et al. EJNMMI Res. .

Abstract

Background: The aim of this study was to assess the reader variability in quantitatively assessing pre- and post-treatment 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography ([18F]FDG PET/CT) scans in a defined set of images of cancer patients using the same semi-automated analytical software (Auto-PERCIST™), which identifies tumor peak standard uptake value corrected for lean body mass (SULpeak) to determine [18F]FDG PET quantitative parameters.

Methods: Paired pre- and post-treatment [18F]FDG PET/CT images from 30 oncologic patients and Auto-PERCIST™ semi-automated software were distributed to 13 readers across US and international sites. One reader was aware of the relevant medical history of the patients (readreference), whereas the 12 other readers were blinded to history but had access to the correlative images. Auto-PERCIST™ was set up to first automatically identify the liver and compute the threshold for tumor measurability (1.5 × liver mean) + (2 × liver standard deviation [SD]) and then detect all sites with SULpeak greater than the threshold. Next, the readers selected sites they believed to represent tumor lesions. The main performance metric assessed was the percent change in the SULpeak (%ΔSULpeak) of the hottest tumor identified on the baseline and follow-up images.

Results: The intra-class correlation coefficient (ICC) for the %ΔSULpeak of the hottest tumor was 0.87 (95%CI: [0.78, 0.92]) when all reads were included (n = 297). Including only the measurements that selected the same target tumor as the readreference (n = 224), the ICC for %ΔSULpeak was 1.00 (95%CI: [1.00, 1.00]). The Krippendorff alpha coefficient for response (complete or partial metabolic response, versus stable or progressive metabolic disease on PET Response Criteria in Solid Tumors 1.0) was 0.91 for all reads (n = 380) and 1.00 including for reads with the same target tumor selection (n = 270).

Conclusion: Quantitative tumor [18F]FDG SULpeak changes measured across multiple global sites and readers utilizing Auto-PERCIST™ show very high correlation. Harmonization of methods to single software, Auto-PERCIST™, resulted in virtually identical extraction of quantitative tumor response data from [18F]FDG PET images when the readers select the same target tumor.

Keywords: Quantification; Response assessment; [18F]FDG PET/CT.

PubMed Disclaimer

Conflict of interest statement

No relevant conflicts of interest were identified except two of the authors, JL and RW, who are co-inventors on a patent underlying the Auto-PERCIST™ software.

Figures

Fig. 1
Fig. 1
Screen captures from Auto-PERCIST™. a The software detected all sites with SULpeak higher than the computed or manually set threshold. b The reader than selected the true tumor lesions (shaded in green), excluding physiologic [18F]FDG activity
Fig. 2
Fig. 2
Bland–Altman plot of the percentage change of tumor [18F]FDG uptake from baseline to follow-up. The plot is for the percentage changes of SULpeak for all reads. Each dot represents a case (30 cases in total). The x-axis represents the average mean percentage change measurement by all readers. The y-axis represents the average difference between the 12 readers and the reference reader (readreference). The solid line represents the average bias, and the dashed lines represent the corresponding bias ± 2 standard deviations (SD)
Fig. 3
Fig. 3
Bland–Altman plot of the percentage change of tumor [18F]FDG uptake from baseline to follow-up. The plot is for the percentage changes of SULpeak (%ΔSULpeak) for only the reads with same lesion selected as the readreference. Each dot represents a case (30 cases in total). The x-axis represents the average mean %ΔSULpeak measurement by all readers. The y-axis represents the average difference between the 12 readers and the reference reader (readreference) and the y-axis unit is one-tenth of one percent. The solid line represents the average bias, and the dashed lines represent the corresponding bias ± 2 standard deviations (SD)
Fig. 4
Fig. 4
a PET maximum intensity projection (MIP) image of patient with right axillary node metastasis at baseline with SULpeak of 1.62 and tumor volume of less than 1.00 cc. Though visually perceptible, Auto-PERCIST™ failed to detect the lesion due to small size. b On the follow-up MIP image, the number of metastatic nodes and the [18F]FDG uptake intensity are increased to SULpeak of 2.84, allowing detection by Auto-PERCIST™

References

    1. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048–3058. doi: 10.1200/JCO.2013.53.5229. - DOI - PMC - PubMed
    1. Gallamini A, Barrington SF, Biggi A, et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica. 2014;99:1107–1113. doi: 10.3324/haematol.2013.103218. - DOI - PMC - PubMed
    1. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol. 1993;11:2101–2111. doi: 10.1200/JCO.1993.11.11.2101. - DOI - PubMed
    1. Connolly RM, Leal JP, Solnes L, et al. TBCRC026: phase II trial correlating standardized uptake value with pathologic complete response to pertuzumab and trastuzumab in breast cancer. J Clin Oncol. 2019;37:714–722. doi: 10.1200/JCO.2018.78.7986. - DOI - PMC - PubMed
    1. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S–150S. doi: 10.2967/jnumed.108.057307. - DOI - PMC - PubMed

LinkOut - more resources